{"id":"W4289856656","doi":"10.36469/jheor.2022.36976","title":"Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective","year":2022,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Discontinuation; Dasatinib; Nilotinib; Internal medicine; Myeloid leukemia; Imatinib; Bosutinib; Pediatrics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007513547,0.0003521988,0.0003155208,0.00130595,0.0003166814,0.001295191,0.0004429923,0.0005908422,0.002988676],"category_scores_gemma":[0.002582252,0.0002367682,0.00104079,0.003996179,0.0002517245,0.000902202,0.0007855581,0.0009851758,0.0001703291],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003793727,"about_ca_system_score_gemma":0.001515709,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.05282079,"about_ca_topic_score_gemma":0.05261017,"domain_scores_codex":[0.9991829,0.0002361931,0.0001263223,0.0001061033,0.0001897081,0.0001587325],"domain_scores_gemma":[0.9978883,0.0002263337,0.001402831,0.00003356293,0.000180356,0.0002686357],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001387264,0.0001004009,0.975455,0.0001586678,0.0003543724,0.0000948541,0.0001176128,0.001505245,0.00007959441,0.001095068,0.01130468,0.009595794],"study_design_scores_gemma":[0.00002469436,0.00006308716,0.9914581,0.0001978459,0.00009867434,0.0002401843,0.0005698921,0.002739262,0.00004765204,0.0003300501,0.004219878,0.00001061382],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9374285,0.01168118,0.0003267872,0.009340159,0.0001514742,0.0001192196,0.03633361,0.00001398259,0.004605132],"genre_scores_gemma":[0.9817564,0.004046203,0.0002645842,0.0009269185,0.0001690728,0.0001005932,0.01226538,0.00000510918,0.0004656565],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05282079,"threshold_uncertainty_score":0.1050267,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06831243107343316,"score_gpt":0.4248905147898626,"score_spread":0.3565780837164295,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}